Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Creators: name: Collier, Dami A.
name: Ferreira, Isabella A. T. M.
name: Kotagiri, Prasanti
name: Datir, Rawlings P.
name: Lim, Eleanor Y.
name: Touizer, Emma
name: Meng, Bo
name: Abdullahi, Adam
name: Elmer, Anne
name: Kingston, Nathalie
name: Graves, Barbara
name: Le Gresley, Emma
name: Caputo, Daniela
name: Bergamaschi, Laura
name: Smith, Kenneth G. C.
name: Bradley, John R.
name: Ceron-Gutierrez, Lourdes
name: Cortes-Acevedo, Paulina
name: Barcenas-Morales, Gabriela
name: Linterman, Michelle A.
name: McCoy, Laura E.
name: Davis, Chris
name: Thomson, Emma
name: McKinney, Eoin
name: Doffinger, Rainer
name: Wills, Mark
name: Gupta, Ravindra K.
name: Baker, Stephen
name: Dougan, Gordon
name: Hess, Christoph
name: Lehner, Paul J.
name: Lyons, Paul A.
name: Matheson, Nicholas J.
name: Owehand, Willem H.
name: Saunders, Caroline
name: Summers, Charlotte
name: Thaventhiran, James E. D.
name: Toshner, Mark
name: Weekes, Michael P.
name: Maxwell, Patrick
name: Shaw, Ashley
name: Bucke, Ashlea
name: Calder, Jo
name: Canna, Laura
name: Domingo, Jason
name: Fuller, Stewart
name: Harris, Julie
name: Hewitt, Sarah
name: Kennet, Jane
name: Jose, Sherly
name: Kourampa, Jenny
name: Meadows, Anne
name: O’Brien, Criona
name: Price, Jane
name: Publico, Cherry
name: Rastall, Rebecca
name: Ribeiro, Carla
name: Rowlands, Jane
name: Ruffolo, Valentina
name: Tordesillas, Hugo
name: Bullman, Ben
name: Dunmore, Benjamin J.
name: Fawke, Stuart
name: Gräf, Stefan
name: Hodgson, Josh
name: Huang, Christopher
name: Hunter, Kelvin
name: Jones, Emma
name: Legchenko, Ekaterina
name: Matara, Cecilia
name: Martin, Jennifer
name: Mescia, Federica
name: O’Donnell, Ciara
name: Pointon, Linda
name: Pond, Nicole
name: Shih, Joy
name: Sutcliffe, Rachel
name: Tilly, Tobias
name: Treacy, Carmen
name: Tong, Zhen
name: Wood, Jennifer
name: Wylot, Marta
name: Betancourt, Ariana
name: Bower, Georgie
name: Cossetti, Chiara
name: De Sa, Aloka
name: Epping, Madeline
name: Gleadall, Nick
name: Grenfell, Richard
name: Hinch, Andrew
name: Huhn, Oisin
name: Jackson, Sarah
name: Jarvis, Isobel
name: Krishna, Ben
name: Lewis, Daniel
name: Marsden, Joe
name: Nice, Francesca
name: Okecha, Georgina
name: Omarjee, Ommar
name: Perera, Marianne
name: Potts, Martin
name: Richoz, Nathan
name: Romashova, Veronika
name: Yarkoni, Natalia Savinykh
name: Sharma, Rahul
name: Stefanucci, Luca
name: Stephens, Jonathan
name: Strezlecki, Mateusz
name: Turner, Lori
name: D. D. De Bie, Eckart M.
name: Bunclark, Katherine
name: Josipovic, Masa
name: Mackay, Michael
name: Michael, Alice
name: Rossi, Sabrina
name: Selvan, Mayurun
name: Spencer, Sarah
name: Yong, Cissy
name: Ansaripour, Ali
name: Mwaura, Lucy
name: Patterson, Caroline
name: Polwarth, Gary
name: Polgarova, Petra
name: Di Stefano, Giovanni
name: Fahey, Codie
name: Michel, Rachel
name: Bong, Sze-How
name: Coudert, Jerome D.
name: Holmes, Elaine
name: Allison, John
name: Butcher, Helen
name: Clapham-Riley, Debbie
name: Dewhurst, Eleanor
name: Furlong, Anita
name: Gray, Jennifer
name: Ivers, Tasmin
name: Kasanicki, Mary
name: Linger, Rachel
name: Meloy, Sarah
name: Muldoon, Francesca
name: Ovington, Nigel
name: Papadia, Sofia
name: Phelan, Isabel
name: Stark, Hannah
name: Stirrups, Kathleen E.
name: Townsend, Paul
name: Walker, Neil
name: Webster, Jennifer
Publisher: name: Apollo - University of Cambridge Repository
Year: 2021
Subjects: Article
/631/250/2152/2153/1291
/631/326/596/4130
/13/106
/38
/38/39
article

description: Abstract: Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age1. Here we analysed immune responses following vaccination with the BNT162b2 mRNA vaccine2 in elderly participants and younger healthcare workers. Serum neutralization and levels of binding IgG or IgA after the first vaccine dose were lower in older individuals, with a marked drop in participants over eighty years old. Sera from participants above eighty showed lower neutralization potency against the B.1.1.7 (Alpha), B.1.351 (Beta) and P.1. (Gamma) VOC than against the wild-type virus and were more likely to lack any neutralization against VOC following the first dose. However, following the second dose, neutralization against VOC was detectable regardless of age. The frequency of SARS-CoV-2 spike-specific memory B cells was higher in elderly responders (whose serum showed neutralization activity) than in non-responders after the first dose. Elderly participants showed a clear reduction in somatic hypermutation of class-switched cells. The production of interferon-γ and interleukin-2 by SARS-CoV-2 spike-specific T cells was lower in older participants, and both cytokines were secreted primarily by CD4 T cells. We conclude that the elderly are a high-risk population and that specific measures to boost vaccine responses in this population are warranted, particularly where variants of concern are circulating.